FDA Classifies Endoscopic Traction Device as Moderate Risk
Published Date: 6/22/2026
Rule
Summary
The FDA is officially putting the endoscopic traction device into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while making it easier for patients to get access to this cool medical tool. The new rules took effect on June 22, 2026, and could speed up innovation without extra costs for makers.
Analyzed Economic Effects
6 provisions identified: 3 benefits, 3 costs, 0 mixed.
Device Classified into Class II
The FDA officially classified the endoscopic traction device as Class II (special controls), effective June 22, 2026 (classification applicable June 13, 2022). FDA says this classification provides reasonable assurance of safety and effectiveness and will enhance patients' access by reducing regulatory burdens.
Device Subject to 510(k) Premarket Notices
FDA states that endoscopic traction devices are subject to premarket notification requirements under section 510(k) of the FD&C Act (i.e., a 510(k) submission is required) at this time.
Special Controls Require Safety Testing
The final order codifies special controls that require in vivo performance testing, non-clinical performance testing, usability assessment, sterility and biocompatibility data, shelf-life demonstration, and specific labeling (including recommended training and safe anatomical locations).
Manufacturers Must Meet Detailed Controls
Manufacturers must meet the codified special controls (testing for perforation, bleeding, device deployment, tensile strength, magnet strength if applicable, sterility, biocompatibility, shelf life, and labeling including recommended training and lesion size guidance) to fall within Class II and avoid automatic Class III assignment.
De Novo Enables Predicate Use for Future Devices
FDA states that because this device was classified via the De Novo process, the endoscopic traction device can serve as a predicate for future devices of that type, allowing other sponsors to use the less burdensome 510(k) process rather than a De Novo or premarket approval.
Device Is Prescription-Only
The final order identifies the endoscopic traction device as a prescription device (prescription use only) and notes prescription devices are exempt from the requirement for adequate directions for layperson use under section 502(f)(1) of the FD&C Act, provided conditions of 21 CFR 801.109 are met.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12443 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple In Vitro Diagnostic Device for the Detection of Secreted Proteins From Bacillus Species (spp.) in Human Clinical Samples
The FDA is officially putting a simple test that spots proteins from Bacillus bacteria in human samples into a safer, easier-to-manage category called Class II. This change helps make sure the test is safe and works well while speeding up patient access to cool new medical tools. The new rules kicked in on June 22, 2026, but have been in effect since February 3, 2023, making life simpler for device makers and patients alike.
2026-12367 — Epizyme, Inc.; Withdrawal of Approval of New Drug Application for TAZVERIK (Tazemetostat) Tablet, 200 Milligrams
Epizyme, Inc. has asked the FDA to withdraw approval for their cancer drug TAZVERIK (200 mg tablets), effective June 22, 2026. This means TAZVERIK will no longer be officially approved for treating certain sarcomas and lymphomas, affecting patients and healthcare providers relying on it. The change might impact treatment options and insurance coverage, so folks should check with their doctors about next steps.
2026-12444 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Light-Projecting Measuring Device
The FDA is officially putting the endoscopic light-projecting measuring device into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while speeding up patient access to cool new tech. The new rules took effect June 22, 2026, and could save time and money for makers and users alike.
2026-12237 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice Regulations for Type A Medicated Articles and Medicated Feeds
The FDA is updating how companies that make special animal medicines and feeds keep their records and follow quality rules. This affects manufacturers of Type A medicated articles and medicated feeds, helping ensure safe and reliable products for animals. Comments on these changes are open until July 20, 2026, and the updates aim to keep things clear without adding extra costs.
2026-12245 — Authorization of Emergency Use for Two Animal Drugs for the Prevention and Treatment of New World Screwworm; Availability
The FDA just gave the green light for two new animal drugs to fight the nasty New World screwworm, a bug that harms cattle, horses, pigs, and even exotic animals. These emergency approvals started in April 2026 to help protect U.S. livestock and wildlife quickly. Farmers, vets, and animal lovers can now use these treatments to stop infestations and keep animals safe without delay.
2026-12235 — Advisory Committee; Science Board to the Food and Drug Administration; Renewal
The FDA is renewing its Science Board for two more years, keeping expert advice flowing to help ensure safe and effective drugs and products. This renewal affects scientists and public health folks who guide the FDA’s big decisions, with the new term lasting until June 26, 2028. No extra costs or delays are expected—just more smart brains working for your health!
Previous / Next Documents
Previous: 2026-12444 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Light-Projecting Measuring Device
The FDA is officially putting the endoscopic light-projecting measuring device into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while speeding up patient access to cool new tech. The new rules took effect June 22, 2026, and could save time and money for makers and users alike.
Next: 2026-12448 — Rescinding the Requirement for Electronic Logging Device Operator's Manual Located in Commercial Motor Vehicles
Starting July 22, 2026, commercial truck drivers no longer have to keep a paper copy of their electronic logging device (ELD) manual in their vehicles. Drivers still need to know how to use their ELDs to keep accurate records and show them during inspections. This change cuts down on paperwork without hurting safety or costing extra money.